Cell Therapy Has a Science Problem and a Factory Problem

The Manufacturing Gap at the Heart of Cell Therapy's Next Chapter

The promise of cell therapy has always run ahead of the factory floor. Since the first approvals arrived in 2017, the field has shown it can eliminate blood cancers with remarkable durability. But taking those same tools to solid tumors, where the disease burden is larger and the immune environment is hostile, has required something the science already had: better manufacturing.

That gap is exactly what Cellular Origins and Immatics are trying to close with a new partnership announced this week. Under the agreement, Immatics will use Cellular Origins' automated mobile robotic platform, called Constellation, within parts of its manufacturing workflow. The goal is to automate selected operations for next-generation cell therapies, making it possible to produce them at scale without the manual labor that has kept costs high and patient access limited.

Cellular Origins CEO Edwin Stone put the problem plainly: current manual manufacturing methods can limit the number of patients who are able to access approved therapies. His company has been building Constellation as a configurable robotic system that integrates across unit operations like cell expansion, harvest, and fill-finish. The platform is designed to work with existing equipment from partners including Fresenius, Cytiva, and Thermo Fisher Scientific rather than replacing them outright.

For Immatics, the partnership arrives at a moment when the science is generating significant momentum. The company has built its pipeline around PRAME, a target expressed in more than 50 cancers, and is advancing TCR T-cell therapies that recognize intracellular tumor peptides presented on the cell surface. At the upcoming ASCO annual meeting in late May in Chicago, Immatics will present four oral abstracts spanning its PRAME-directed cell therapy candidates and a bispecific asset called IMA401 across multiple solid tumor indications.

The clinical data that has drawn the most attention is a case report of a 17-year-old patient with advanced metastatic nephroblastoma who had no remaining treatment options. After receiving a PRAME-directed TCR T-cell therapy manufactured specifically for this individual at Heidelberg University Hospital, the patient achieved molecular remission at six months of follow-up. Imaging showed regression across all lesion sites including lung, liver, and brain metastases from an original abdominal tumor measuring 16 centimeters in its longest diameter. The treating physician described the response as deeply encouraging for the field.

That kind of result does not change the manufacturing problem. A therapy that works beautifully in a case report still has to be made reliably and affordably for the patients who need it. Manual cell therapy manufacturing is labor intensive and difficult to standardize, which is why academic medical centers and biotechs alike have been looking to automation to bridge the gap between what the science can do and what the supply chain can deliver.

Immatics has emphasized that developing manufacturing capabilities capable of supporting future scale is a parallel priority to the clinical programs themselves. The Cellular Origins partnership reflects that priority: rather than building its own manufacturing infrastructure from scratch, Immatics is plugging into an automated platform that can be configured for different therapy types and production volumes.

Solid tumor cell therapies remain early. The 2017 approvals validated the approach in blood cancers, but progress in solid tumors has been more gradual for reasons that include tumor microenvironment immunosuppression and difficulty identifying targets that are both tumor-specific and presented reliably on HLA molecules. PRAME has emerged as one of the more compelling targets in part because of its expression pattern across multiple cancer types, but the clinical data is still accumulating.

What the Immatics-Cellular Origins partnership signals is that at least one company is betting the manufacturing problem will be solved on a similar timeline to the biological one. If Constellation can demonstrate that Immatics' PRAME-directed therapies can be produced at commercial scale with consistent quality, it removes one of the key uncertainties hanging over the field. Patients and physicians are watching both fronts.

The collaboration is exploratory in important respects. Neither company has disclosed specific timelines or production targets, and the work will initially focus on selected parts of Immatics' manufacturing process rather than a full end-to-end automation rollout. But the direction is clear: the science is ready for more patients. The question is whether the factory can follow.